MCID: GST053
MIFTS: 77

Gastric Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastric Cancer

MalaCards integrated aliases for Gastric Cancer:

Name: Gastric Cancer 57 38 12 53 75 37 55
Stomach Cancer 12 76 53 75 29 43 15
Stomach Carcinoma 12 53 15 73
Malignant Tumor of Lesser Curve of Stomach 12 73
Malignant Neoplasm of Body of Stomach 12 73
Neoplasm of Stomach 29 6
Gastric Carcinoma 12 55
Stomach Neoplasms 44 73
Malignant Neoplasm of Lesser Curve of Stomach 12
Malignant Tumor of Greater Curve of Stomach 12
Malignant Tumor of Body of Stomach 12
Ca Greater Curvature of Stomach 12
Ca Lesser Curvature - Stomach 12
Malignant Neoplasm of Stomach 73
Gastric Cancer Intestinal 75
Gastric Cancer, Somatic 57
Adult Stomach Carcinoma 53
Cancer of the Stomach 12
Carcinoma of Stomach 12
Adult Stomach Cancer 53
Ca Body - Stomach 12
Gastric Neoplasm 12
Cancer, Gastric 40
Gasc 75

Characteristics:

HPO:

32
gastric cancer:
Inheritance somatic mutation


Classifications:



Summaries for Gastric Cancer

NIH Rare Diseases : 53 Stomach cancer, also called gastric cancer, is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the stomach. Most people with early stomach cancer have no signs or symptoms of the condition. In advanced stages, symptoms may include indigestion; nausea and vomiting; difficulty swallowing; feeling full after eating small amounts of food; loss of appetite; vomiting blood; fatigue; and/or weight loss. Most cases of stomach cancer occur sporadically in people with little to no family history of the condition; however, approximately 10% of stomach cancers are considered "familial." Although the underlying cause of some familial cases is unknown, genetic changes (mutations) are identified in a subset of people affected by stomach cancer. Hereditary cancer syndromes associated with a predisposition to stomach cancer include hereditary diffuse gastric cancer, Lynch syndrome, Li-Fraumeni syndrome, familial adenomatous polyposis, and Peutz-Jeghers syndrome. In other families, a cluster of stomach cancers may be due to a combination of gene(s) and/or other shared factors such as environment and lifestyle. The best treatment options for stomach cancer depend on many factors including the stage of the condition and may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

MalaCards based summary : Gastric Cancer, also known as stomach cancer, is related to gastric adenocarcinoma and colorectal cancer, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Gastric Cancer is APC (APC, WNT Signaling Pathway Regulator), and among its related pathways/superpathways are Gastric cancer and PI3K-Akt signaling pathway. The drugs Cyramza and Herceptin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and lung, and related phenotypes are stomach cancer and increased level of l-fucose in urine

OMIM : 57 In a review article on the genetic predisposition to gastric cancer, Bevan and Houlston (1999) concluded that several genes may be associated with an increased risk of gastric cancer. Gastric cancer is a manifestation of a number of inherited cancer predisposition syndromes, including hereditary nonpolyposis colon cancer (HNPCC1; see 120435), familial adenomatous polyposis (FAP; 175100), Peutz-Jeghers syndrome (PJS; 175200), Cowden disease (CD; 158350), and the Li-Fraumeni syndrome (151623). See also hereditary diffuse gastric cancer (HDGC; 137215). Canedo et al. (2007) provided a review of genetic susceptibility to gastric cancer in patients infected with Helicobacter pylori (see 600263). (613659)

UniProtKB/Swiss-Prot : 75 Gastric cancer: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.

MedlinePlus : 43 The stomach is an organ between the esophagus and the small intestine. It mixes food with stomach acid and helps digest protein. Stomach cancer mostly affects older people - two-thirds of people who have it are over age 65. Your risk of getting it is also higher if you Have had a Helicobacter pylori infection Have had stomach inflammation Are a man Eat lots of salted, smoked, or pickled foods Smoke cigarettes Have a family history of stomach cancer It is hard to diagnose stomach cancer in its early stages. Indigestion and stomach discomfort can be symptoms of early cancer, but other problems can cause the same symptoms. In advanced cases, there may be blood in your stool, vomiting, unexplained weight loss, jaundice, or trouble swallowing. Doctors diagnose stomach cancer with a physical exam, blood and imaging tests, an endoscopy, and a biopsy. Because it is often found late, it can be hard to treat stomach cancer. Treatment options include surgery, chemotherapy, radiation or a combination. NIH: National Cancer Institute

Disease Ontology : 12 A gastrointestinal system cancer that is located in the stomach.

Wikipedia : 76 Stomach cancer, also known as gastric cancer, is cancer developing from the lining of the stomach. Early... more...

Related Diseases for Gastric Cancer

Diseases related to Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 362)
# Related Disease Score Top Affiliating Genes
1 gastric adenocarcinoma 34.6 APC ERBB2 FGFR2 KRAS PIK3CA
2 colorectal cancer 34.0 APC ERBB2 KRAS MIR106B MIR141 MIR145
3 breast cancer 33.8 APC ERBB2 FGFR2 KRAS MIR141 MIR145
4 prostate cancer 33.4 ERBB2 FGFR2 KLF6 KRAS MIR106B MIR141
5 lung cancer 33.2 ERBB2 FGFR2 IRF1 KRAS MIR141 MIR145
6 adenocarcinoma 33.2 APC ERBB2 FGFR2 KRAS PIK3CA
7 hepatocellular carcinoma 33.2 APC KRAS MIR106B MIR141 MIR145 MIR203A
8 pancreatic cancer 32.9 ERBB2 KRAS MIR203A MIR20A MIR21 MIR221
9 esophageal cancer 32.8 ERBB2 KRAS MIR203A MIR21 MIR34A PIK3CA
10 melanoma 32.5 MIR141 MIR200C MIR221 MIR27A MIR34A
11 cholangiocarcinoma 32.3 ERBB2 FGFR2 KRAS MIR141 MIR21 PIK3CA
12 glioma 32.1 ERBB2 MIR20A MIR21 MIR221 MIR25 MIR34A
13 familial adenomatous polyposis 32.0 APC KRAS MUTYH
14 dermatomyositis 31.9 MIR21 MIR221 MIR34A
15 pancreatic ductal adenocarcinoma 31.9 MIR141 MIR145 MIR203A MIR21 MIR221
16 colorectal adenoma 31.9 APC KRAS MUTYH
17 lung cancer susceptibility 3 31.8 APC ERBB2 KRAS PIK3CA
18 attenuated familial adenomatous polyposis 31.3 APC MUTYH
19 leukemia, acute myeloid 31.0 KRAS MIR21 MIR221 MIR27A
20 gastric cancer, hereditary diffuse 12.7
21 diffuse gastric cancer 12.4
22 microinvasive gastric cancer 12.2
23 stomach carcinoma in situ 12.1
24 epstein-barr virus-associated gastric carcinoma 12.1
25 ovarian cancer 12.0 ERBB2 KRAS MIR106B MIR141 MIR200C MIR21
26 carcinoma of stomach, salivary gland type 12.0
27 undifferentiated carcinoma of stomach 12.0
28 adamantinoma of long bones 11.9 APC ERBB2 KRAS MIR141 MIR200C PIK3CA
29 leukemia, chronic lymphocytic 11.9 KRAS MIR106B MIR141 MIR145 MIR21 MIR221
30 oral squamous cell carcinoma 11.9 MIR145 MIR200C MIR203A MIR21 MIR221 MIR27A
31 endometrial cancer 11.9 ERBB2 FGFR2 KRAS MIR200C MUTYH PIK3CA
32 kidney cancer 11.9 MIR106B MIR141 MIR200C MIR20A MIR21 MIR27A
33 glioblastoma 11.9 ERBB2 MIR21 MIR221 MIR25 MIR34A PIK3CA
34 bladder cancer 11.8 ERBB2 KRAS MIR145 MIR203A MIR21 MIR221
35 squamous cell carcinoma, head and neck 11.8 ERBB2 MIR141 MIR21 MIR221 PIK3CA
36 gastrointestinal system cancer 11.8 ERBB2 KRAS MUTYH PIK3CA
37 esophagus adenocarcinoma 11.8 ERBB2 MIR145 MIR21 PIK3CA
38 ovarian serous carcinoma 11.7 MIR141 MIR145 MIR21 MIR27A
39 medulloblastoma 11.7 APC ERBB2 MIR20A MIR34A PIK3CA
40 hyperplastic polyposis syndrome 11.7 APC KRAS MUTYH
41 nonalcoholic fatty liver disease 11.7 MIR200C MIR203A MIR27A MIR34A
42 mutyh-associated polyposis 11.7 APC KRAS MUTYH
43 leukemia, acute lymphoblastic 11.7 MIR203A MIR21 MIR221 MIR27A
44 acneiform dermatitis 11.7 ERBB2 KRAS PIK3CA
45 adenosquamous cell lung carcinoma 11.7 ERBB2 KRAS PIK3CA
46 intestinal benign neoplasm 11.7 APC KRAS MUTYH
47 ovarian cancer 1 11.6 ERBB2 KRAS PIK3CA
48 malignant ovarian surface epithelial-stromal neoplasm 11.6 ERBB2 KRAS PIK3CA
49 ovary epithelial cancer 11.6 ERBB2 KRAS PIK3CA
50 endometrial adenocarcinoma 11.6 ERBB2 FGFR2 KRAS

Comorbidity relations with Gastric Cancer via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Gastric Fundus Cancer
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Neutropenia
Protein-Energy Malnutrition Pylorus Cancer
Stomach Carcinoma in Situ

Graphical network of the top 20 diseases related to Gastric Cancer:



Diseases related to Gastric Cancer

Symptoms & Phenotypes for Gastric Cancer

Clinical features from OMIM:

613659

Human phenotypes related to Gastric Cancer:

32
# Description HPO Frequency HPO Source Accession
1 stomach cancer 32 HP:0012126
2 increased level of l-fucose in urine 32 HP:0410067

UMLS symptoms related to Gastric Cancer:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

MGI Mouse Phenotypes related to Gastric Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 APC ERBB2 FGFR2 IRF1 KRAS MUTYH

Drugs & Therapeutics for Gastric Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Cyramza 18 49 RAMUCIRUMAB Eli Lilly April 2014
2
Herceptin 18 49 TRASTUZUMAB Genentech October 1998
3
Iressa 18 49 GEFITINIB AstraZeneca May 2003

Drugs for Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 555)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
2
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
3
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 180288-69-1 9903
4
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
5
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
6
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
7
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
8
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 100986-85-4 149096
9
Ofloxacin Approved Phase 4,Phase 3,Phase 1 82419-36-1 4583
10
Pravastatin Approved Phase 4 81093-37-0 54687
11
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
12
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
13
Pantoprazole Approved Phase 4,Not Applicable 102625-70-7 4679
14
Ticlopidine Approved Phase 4 55142-85-3 5472
15
Ecabet Approved, Investigational Phase 4 33159-27-2, 86408-72-2 65781
16
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
17
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 138530-94-6, 103577-45-3 9578005
18
Lansoprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 103577-45-3 3883
19
Famotidine Approved Phase 4,Phase 1 76824-35-6 3325
20
Histamine Approved, Investigational Phase 4,Phase 1,Not Applicable 75614-87-8, 51-45-6 774
21
Metronidazole Approved Phase 4,Phase 3,Phase 1 443-48-1 4173
22
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 73590-58-6 4594
23
Etomidate Approved Phase 4 33125-97-2 36339 667484
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
25
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
26
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
27
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
28
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 97682-44-5, 100286-90-6 60838
29
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
30
Iron Approved Phase 4,Phase 3,Not Applicable 7439-89-6 23925
31
Tinidazole Approved, Investigational Phase 4,Phase 3 19387-91-8 5479
32
Zinc Approved, Investigational Phase 4,Phase 2 7440-66-6 23994
33
Floxuridine Approved Phase 4,Phase 3,Phase 2,Phase 1 50-91-9 5790
34
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3 7487-88-9 24083
35
Simethicone Approved Phase 4 8050-81-5
36
Morphine Approved, Investigational Phase 4 57-27-2 5288826
37
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 71273 175805
38
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 68602 5311068
39
Coal tar Approved Phase 4 8007-45-2
40
Tetracycline Approved, Vet_approved Phase 4,Phase 3 60-54-8 5353990
41
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
42
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
43
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
44
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 117976-89-3 5029
45
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 93-14-1 3516
46
Furazolidone Approved, Investigational, Vet_approved Phase 4 67-45-8 3435 5323714
47
Loperamide Approved Phase 4,Not Applicable 53179-11-6 3955
48
Pectin Approved, Investigational, Vet_approved Phase 4 9000-69-5 441476
49
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3 564-25-0 54671203
50
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 3,Not Applicable 1406-66-2 14986

Interventional clinical trials:

(show top 50) (show all 1759)
# Name Status NCT ID Phase Drugs
1 Gastrectomy Plus Prophylactic Cholecystectomy in Gastric Cancer Surgery Unknown status NCT00757640 Phase 4
2 A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy Unknown status NCT02776527 Phase 4 Apatinib Mesylate Tablets
3 Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients Unknown status NCT01910948 Phase 4 omega-3 polyunsaturated fatty acids
4 Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
5 Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
6 Early Jejunostomy Nutrition Minimizes Time to Chemotherapy Unknown status NCT01766765 Phase 4
7 Community-based Helicobacter Pylori Eradication Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
8 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
9 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
10 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
11 Effect of Helicobacter Pylori on the Availability of Vitamin E and C Unknown status NCT00303160 Phase 4 vitamin C & E supplements
12 Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection Unknown status NCT01308177 Phase 4 Ecabet
13 Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
14 Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
15 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
16 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
17 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
18 Combined Use of Etomidate and Propofol in Painless Gastroscopy. Unknown status NCT01913054 Phase 4 Fentanyl Injection;Etomidate Fat Emulsion Injection;Propofol Injection
19 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
20 Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection Completed NCT01914692 Phase 4 Somatostatin
21 RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients Completed NCT01401075 Phase 4 mistletoe extract;doxifluridine
22 Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor Completed NCT01579071 Phase 4
23 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4 Magnesium Sulfate;Normal saline
24 Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy Completed NCT01653171 Phase 4 Water (Placebo);Simethicone;N-acetylcysteine 500 mg;N-acetylcysteine 1000 mg
25 Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia Completed NCT01471756 Phase 4
26 Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02458573 Phase 4
27 Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study- Completed NCT01234272 Phase 4 morphine;Ropivacaine
28 The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02164448 Phase 4 the dexmedetomidine group;the control group
29 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
30 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
31 Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection Completed NCT00656968 Phase 4 10-day sequential treatment;10-day concomitant therapy
32 The Effect of Nutritional Counseling for Cancer Patients Completed NCT01962272 Phase 4
33 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
34 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
35 The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study Completed NCT00885417 Phase 4 Cravit-based sequential therapy
36 Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori Completed NCT01042184 Phase 4 Sequential therapy for 14 days;Sequential therapy for 10 days;Triple therapy for 14 days
37 The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection Completed NCT01032655 Phase 4 susceptibility test guided sequential therapy
38 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
39 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
40 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
41 Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality Recruiting NCT02047994 Phase 4 Triple therapy
42 Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer Recruiting NCT02401971 Phase 4 Thalidomide;CPT-11
43 Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD. Recruiting NCT02638584 Phase 4 Ilaprazole;Rabeprazole
44 Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Recruiting NCT02426034 Phase 4 Apatinib
45 Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations Recruiting NCT03475589 Phase 4 apatinib
46 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
47 Laparoscopic Versus Open Resection of Cancer Stomach Recruiting NCT02789826 Phase 4
48 Iron Replacement in Oesophagogastric Neoplasia Recruiting NCT01927328 Phase 4 Iron isomaltoside 1000
49 Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection Recruiting NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
50 Intraluminal Clarithromycin Powder Monotherapy for Helicobacter Pylori Infection Recruiting NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin

Search NIH Clinical Center for Gastric Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: stomach neoplasms

Genetic Tests for Gastric Cancer

Genetic tests related to Gastric Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Stomach 29 APC CASP10 ERBB2 FGFR2 IRF1 KLF6 MUTYH PIK3CA
2 Stomach Cancer 29

Anatomical Context for Gastric Cancer

MalaCards organs/tissues related to Gastric Cancer:

41
Lymph Node, Liver, Lung, Testes, Breast, Endothelial, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Gastric Cancer:

19
The Stomach

Publications for Gastric Cancer

Articles related to Gastric Cancer:

(show top 50) (show all 11066)
# Title Authors Year
1
Risk Factors for Anastomotic Leakage of Esophagojejunostomy after Laparoscopy-Assisted Total Gastrectomy for Gastric Cancer. ( 28441658 )
2018
2
Isolated breast metastasis from gastric cancer in a male patient. ( 29302921 )
2018
3
GSDME mediates caspase-3-dependent pyroptosis in gastric cancer. ( 29183726 )
2018
4
VDR independent induction of acid-sphingomyelinase by 1,23(OH)<sub>2</sub>D<sub>3</sub>in gastric cancer cells: Impact on apoptosis and cell morphology. ( 29158006 )
2018
5
Overexpression of NEK3 is associated with poor prognosis in patients with gastric cancer. ( 29504992 )
2018
6
Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. ( 29706558 )
2018
7
Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand MA8ori. ( 29589180 )
2018
8
Role of germline aberrations affecting<i>CTNNA1</i>,<i>MAP3K6</i>and<i>MYD88</i>in gastric cancer susceptibility. ( 29330337 )
2018
9
MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1. ( 29054762 )
2018
10
Superficial Spreading-type Gastric Cancer with <i>Situs Inversus Totalis</i>. ( 29695579 )
2018
11
Upregulation of ZBTB7A exhibits a tumor suppressive role in gastric cancer cells. ( 29207095 )
2018
12
Discriminating gastric cancer and gastric ulcer using human plasma amino acid metabolic profile. ( 29626382 )
2018
13
Inhibition of two gastric cancer cell lines induced by fucoxanthin involves downregulation of Mcl-1 and STAT3. ( 29110251 )
2018
14
Human epidermal growth factor receptor 2 expressions and Janus-activated kinase/signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway may be associated with clinicopathological features and prognosis of gastric cancer. ( 29970682 )
2018
15
Long noncoding RNA LINC00978 promotes cancer growth and acts as a diagnostic biomarker in gastric cancer. ( 29271006 )
2018
16
DDIT4 promotes gastric cancer proliferation and tumorigenesis through the p53 and MAPK pathways. ( 29976242 )
2018
17
Impact of SNP-SNP interactions of DNA repair gene<i>ERCC5</i>and metabolic gene<i>GSTP1</i>on gastric cancer/atrophic gastritis risk in a Chinese population. ( 29434449 )
2018
18
FBXO31 Suppresses Gastric Cancer EMT by Targeting Snail1 for Proteasomal Degradation. ( 29117943 )
2018
19
Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. ( 29306868 )
2018
20
Robot-assisted distal gastrectomy with lymph node dissection for gastric cancer in a patient with situs inversus partialis: a case report with video file. ( 29441475 )
2018
21
Aberrant GATA2 epigenetic dysregulation induces a GATA2/GATA6 switch in human gastric cancer. ( 29106391 )
2018
22
STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy. ( 29329543 )
2018
23
SPP1 rs4754 and its epistatic interactions with SPARC polymorphisms in gastric cancer susceptibility. ( 28962925 )
2018
24
The Epithelial-Mesenchymal Transition Pathway in Two Cases with Gastric Metastasis Originating from Breast Carcinoma, One with a Metachronous Primary Gastric Cancer. ( 29090670 )
2018
25
Association between density of tumor-infiltrating lymphocytes and prognoses of patients with gastric cancer. ( 29979429 )
2018
26
Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). ( 29189914 )
2018
27
LncRNA SNHG12 regulates gastric cancer progression by acting as a molecular sponge of miRa89320. ( 29207106 )
2018
28
Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center. ( 29329569 )
2018
29
MiR-93-5p promotes gastric cancer-cell progression via inactivation of the Hippo signaling pathway. ( 29045821 )
2018
30
Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth. ( 29435734 )
2018
31
miR-21 Inhibitors Modulate Biological Functions of Gastric Cancer Cells via PTEN/PI3K/mTOR Pathway. ( 29185784 )
2018
32
miR-135b-5p promotes gastric cancer progression by targeting CMTM3. ( 29345297 )
2018
33
Overexpression of lncRNA LINC01793 acts as a potential predictor for progression and poor prognosis of gastric cancer. ( 29978448 )
2018
34
BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC. ( 28681984 )
2018
35
PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. ( 29034543 )
2018
36
Gastrectomy with limited surgery for elderly patients with gastric cancer. ( 27693065 )
2018
37
Screening Biomarker as an Alternative to Endoscopy for the Detection of Early Gastric Cancer: The Combination of Serum Trefoil Factor Family 3 and Pepsinogen. ( 29977284 )
2018
38
A novel design of HA-coated nanoparticles co-encapsulating plasmid METase and 5-Fu shows enhanced application in targeting gastric cancer stem cells. ( 29016350 )
2018
39
Prior gastroscopy and mortality in patients with gastric cancer: a matched retrospective cohort study. ( 28648576 )
2018
40
ASSOCIATION OF INTERLEUKIN-10 -1082 A/G (RS1800896) POLYMORPHISM WITH SUSCEPTIBILITY TO GASTRIC CANCER: META-ANALYSIS OF 6,101 CASES AND 8,557 CONTROLS. ( 29561974 )
2018
41
Case report about a successful full robotic radical gastric cancer surgery with intracorporeal robot-sewn anastomosis in a patient with situs inversus totalis and a two-and-a-half-year follow-up study. ( 29499701 )
2018
42
BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells. ( 29393385 )
2018
43
Lysyl oxidase activates cancer stromal cells and promotes gastric cancer progression: quantum dot-based identification of biomarkers in cancer stromal cells. ( 29343955 )
2018
44
Hereditary diffuse gastric cancer: how to look for and how to manage it. ( 29869323 )
2018
45
Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. ( 29465762 )
2018
46
Health Barriers and Patterns of Gastric Cancer Care in Rural Central American Resource-Limited Settings. ( 29978182 )
2018
47
Molecular and Pathological Features of Gastric Cancer in Lynch Syndrome and Familial Adenomatous Polyposis. ( 29882764 )
2018
48
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT. ( 29443079 )
2018
49
Preoperative Tumor Markers Independently Predict Survival in Stage III Gastric Cancer Patients: Should We Include Tumor Markers in AJCC Staging? ( 29971670 )
2018
50
G9A promotes gastric cancer metastasis by upregulating ITGB3 in a SET domain-independent manner. ( 29449539 )
2018

Variations for Gastric Cancer

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer:

75 (show all 19)
# Symbol AA change Variation ID SNP ID
1 APC p.Gly817Cys VAR_005035
2 APC p.Ile880Thr VAR_005036
3 APC p.Asn942Asp VAR_005039
4 APC p.Gly1120Glu VAR_005042 rs28933379
5 APC p.Arg1171His VAR_005043 rs372481703
6 APC p.Phe1197Ser VAR_005045
7 APC p.Ile1259Thr VAR_005046
8 APC p.Gly1312Glu VAR_005050
9 APC p.Val1326Ala VAR_005052
10 CASP10 p.Met147Thr VAR_037428 rs121909776
11 IRF1 p.Met8Leu VAR_065134 rs121912469
12 IRF1 p.Trp11Arg VAR_065135 rs121912470
13 KRAS p.Gly12Val VAR_006840 rs121913529
14 KRAS p.Gly12Asp VAR_016026 rs121913529
15 KRAS p.Gly12Ser VAR_016028